These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35458724)

  • 1. Docking, Binding Free Energy Calculations and In Vitro Characterization of Pyrazine Linked 2-Aminobenzamides as Novel Class I Histone Deacetylase (HDAC) Inhibitors.
    Bülbül EF; Melesina J; Ibrahim HS; Abdelsalam M; Vecchio A; Robaa D; Zessin M; Schutkowski M; Sippl W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity.
    Ibrahim HS; Abdelsalam M; Zeyn Y; Zessin M; Mustafa AM; Fischer MA; Zeyen P; Sun P; Bülbül EF; Vecchio A; Erdmann F; Schmidt M; Robaa D; Barinka C; Romier C; Schutkowski M; Krämer OH; Sippl W
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Biological Evaluation of New HDAC1 and HDAC2 Inhibitors Endowed with Ligustrazine as a Novel Cap Moiety.
    Al-Sanea MM; Gotina L; Mohamed MF; Grace Thomas Parambi D; Gomaa HAM; Mathew B; Youssif BGM; Alharbi KS; Elsayed ZM; Abdelgawad MA; Eldehna WM
    Drug Des Devel Ther; 2020; 14():497-508. PubMed ID: 32103894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
    Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
    Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel polysubstituted
    Wang Z; Zhao L; Zhang B; Feng J; Wang Y; Zhang B; Jin H; Ding L; Wang N; He S
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2206581. PubMed ID: 37144599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines.
    Abdelsalam M; Ibrahim HS; Krauss L; Zessin M; Vecchio A; Hastreiter S; Schutkowski M; Schneider G; Sippl W
    Methods Mol Biol; 2023; 2589():145-155. PubMed ID: 36255623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
    Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
    Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding Free Energy (BFE) Calculations and Quantitative Structure-Activity Relationship (QSAR) Analysis of
    Simoben CV; Ghazy E; Zeyen P; Darwish S; Schmidt M; Romier C; Robaa D; Sippl W
    Molecules; 2021 Apr; 26(9):. PubMed ID: 33925246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.
    Wagner FF; Weïwer M; Steinbacher S; Schomburg A; Reinemer P; Gale JP; Campbell AJ; Fisher SL; Zhao WN; Reis SA; Hennig KM; Thomas M; Müller P; Jefson MR; Fass DM; Haggarty SJ; Zhang YL; Holson EB
    Bioorg Med Chem; 2016 Sep; 24(18):4008-4015. PubMed ID: 27377864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
    Mao PT; He WB; Mai X; Feng LH; Li N; Liao YJ; Zhu CS; Li J; Chen T; Liu SH; Zhang QM; He L
    Bioorg Med Chem; 2022 Feb; 56():116599. PubMed ID: 35041998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
    Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
    Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
    Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
    Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
    Gupta R; Ambasta RK; Kumar P
    Life Sci; 2020 Sep; 256():117912. PubMed ID: 32504755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of histone deacetylase inhibitor with novel salicylamide zinc binding group.
    Kim JH; Ali KH; Oh YJ; Seo YH
    Medicine (Baltimore); 2022 Apr; 101(17):e29049. PubMed ID: 35512065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.